Survivin study: An update of "what is the next wave?"

Journal of Cellular Physiology

Volumn 208, Issue 3, 2006, Pages 476-486

  Li, Fengzhi ^a,b,c   Ling, Xiang ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b TONGJI UNIVERSITY   (China)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; DOXORUBICIN; PACLITAXEL; PEPTIDE DERIVATIVE; RESVERATROL; SHEPHERDIN; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CELLULAR DISTRIBUTION; CHEMOPROPHYLAXIS; DRUG RESISTANCE; EXON; HUMAN; MITOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; REVIEW;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; CELL PHYSIOLOGY; COMPUTATIONAL BIOLOGY; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; RNA, MESSENGER; SEQUENCE DELETION; VARIATION (GENETICS);

EID: 33745692998     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20634     Document Type: Review

References (70)

1. Aziz M, Afaq F, Ahmad N. 2005a. Prevention of ultraviolet B radiation damage by resveratrol in mouse skin is mediated via modulation in Survivin. Photochem Photobiol 81(1):25-31.
2. Aziz MH, Reagan-Shaw S, Wu J, Longley BJ, Ahmad N. 2005b. Chemoprevention of skin cancer by grape constituent resveratrol: Relevance to human disease? FASEB J 19(9):1193-1195.
3. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M. 2004. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 314(3):902-907.
4. Beardmore VA, Ahonen LJ, Gorbsky GJ, Kallio MJ. 2004. Survivin dynamics increases at centromeres during G2/M phase transition and is regulated by microtubule-attachment and Aurora B kinase activity. J Cell Sci 117(Pt 18):4033-4042.
5. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simoes-Wust AP, Yousefi S, Simon HU, Stahel R, Zangemeister-Wittke U. 2005. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 117(5):755-763.
6. Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman D. 2003. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol 120(1):48-55.
7. Caldas H, Honsey LE, Altura RA. 2005a. Survivin 2alpha: A novel Survivin splice variant expressed in human malignancies. Mol Cancer 4(1):11.
8. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA. 2005b. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24(12):1994-2007.
9. Cao C, Mu Y, Hallahan DE, Lu B. 2004. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23(42):7047-7052.
10. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. 2003. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 116(Pt 14):2987-2998.
11. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J. 2004. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23(45):7494-7506.
12. Delacour-Larose M, Molla A, Skoufias DA, Margolis RL, Dimitrov S. 2004. Distinct dynamics of Aurora B and Survivin during Mitosis. Cell Cycle 3(11):1418-1426.
13. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. 2004a. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114(8):1117-1127.
14. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC, Altieri DC. 2004b. An IAP-IAP complex inhibits apoptosis. J Biol Chem 279(33):34087-34090.
15. Earnshaw WC. 2005. Cell biology. Keeping survivin nimble at centromeres in mitosis. Science 310(5753):1443-1444.
16. Endoh T, Tsuji N, Asanuma K, Yagihashi A, Watanabe N. 2005. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res 305(2):300-311.
17. Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, Porta CA. 2004. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9(5):573-582.
18. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, Sessa WC, Altieri DC. 2003. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 100(24):13791-13796.
19. Fukuda S, Pelus LM. 2001. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: Implication of survivin expression in normal hematopoiesis. Blood 98(7):2091-2100.
20. Fukuda S, Foster RG, Porter SB, Pelus LM. 2002. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 100(7):2463-2471.
21. Fulda S, Debatin KM. 2004a. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 23(40):6702-6711.
22. Fulda S, Debatin KM. 2004b. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 64(1):337-346.
23. Gurbuxani S, Xu Y, Keerthivasan G, Wickrema A, Crispino JD. 2005. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci USA 102(32):11480-11485.
24. Hayashi N, Asano K, Suzuki H, Yamamoto T, Tanigawa N, Egawa S, Manome Y. 2005. Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 65(1):10-19.
25. Honda R, Korner R, Nigg EA. 2003. Exploring the functional interactions between Aurora B, INCENP, and Survivin in Mitosis. Mol Biol Cell 14(8):3325-3341.
26. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Kawaguchi Y, Fujimoto K, Wada M, Miyatake S, Imamura M. 2005. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 138(2):299-305.
27. Kappler M, Taubert H, Bartel F, Blumke K, Panian M, Schmidt H, Dunst J, Bache M. 2005. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 13(1):167-172.
28. Krysan K, Dalwadi H, Sharma S, Pold M, Dubinett S. 2004a. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 64(18):6359-6362.
29. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Fold M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S. 2004b. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 18(1):206-208.
30. Kuo PC, Liu HF, Chao JL. 2004. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in the human lung carcinoma cells. J Biol Chem 279(53):55875-55885.
31. Lens SM, Medema RH. 2003. The survivin/aurora B complex: Its role in coordinating tension and attachment. Cell Cycle 2(6):507-510.
32. Li F. 2003. Survivin Study: What is the next wave? J Cell Physiol 197(1):8-29.
33. Li F. 2005a. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92(2):212-216.
34. Li F. 2005b. Role of survivin in cancer chemoprevention. Assay Des-Simply Sci 1(1):2-6.
35. Li F. 2005e. Survivin, other IAPs, Smac/DIABLO, and Omi/HtrA2-modulation of the advancing apoptotic process. In: Los M, Gibson SB, editors. Apoptotic pathways as target for novel therapies in cancer and other diseases. New York: Kluwer Press, pp 137-155.
36. Li F, Brattain MG. 2006. Role of the survivin gene in pathophysiology. Am J Pathol in press.
37. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. 1998. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396(6711):580-584.
38. Li F, Ling X, Huang H, Brattain L, Apontes P, Wu J, Binderup L, Brattain MG. 2005. Differential regulation of survivin expression and apoptosis by vitamin D(3) compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 24(8):1385-1395.
39. Ling X, Bernacki RJ, Brattain MG, Li F. 2004. Induction of survivin expression by taxol (paclitaxel) is an early event which is independent on taxol-mediated G2/M arrest. J Biol Chem 279(15):15196-15203.
40. Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, Slocum HK, Yang L, Zhou M, Li F. 2005. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 49:353-361.
41. Liu T, Brouha B, Grossman D. 2004. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survival-targeted melanoma cells. Oncogene 23(1):39-48.
42. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, Gerharz CD. 2002. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 9(12):1334-1342.
43. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, Reed JC, 2003. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 22(11):2729-2740.
44. Nagata Y, Jones MR, Nguyen HG, McCrann DJ, St Hilaire C, Schreiber BM, Hashimoto A, Inagaki M, Earnshaw WC, Todokoro K, Ravid K. 2005. Vascular smooth muscle cell polyploidization involves changes in chromosome passenger proteins and an endomitotic cell cycle. Exp Cell Res 305(2):277-291.
45. Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ko Ferrigno P, Wheatley SP. 2006. Molecular analysis of survivin isoforms: Evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 281:1286-1295.
46. O'Connor DS, Wall NR, Porter AC, Altieri DC. 2002. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2(1):43-54.
47. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. 2003. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9(17):6523-6533.
48. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI, Colombo G, Altieri DC. 2005. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7(5):457-468.
49. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F. 2003. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: Survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55(5):1341-1347.
50. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C. 2005. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65(11):4881-4887.
51. Sampath SC, Ohi R, Leismann O, Salic A, Pozniakovski A, Funabiki H. 2004. The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly. Cell 118(2):187-202.
52. Samuel T, Okada K, Hyer M, Welsh K, Zapata JM, Reed JC. 2005. cIAP1 localizes to the nuclear compartment and modulates the cell cycle. Cancer Res 65(1):210-218.
53. Song Z, Wu M. 2005. Identification of a novel nucleolar localization signal and a degradation signal in Survivin-del taEx3: A potential link between nucleolus and protein degradation. Oncogene 24(16):2723-2734.
54. Suga K, Yamamoto T, Yamada Y, Miyatake S, Nakagawa T, Tanigawa N. 2005. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep 13(5):891-897.
55. Sui M, Fan W. 2005. Combination of gamma-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis. Int J Radiat Oncol Biol Phys 61(4):1151-1158.
56. Taubert H, Kappler M, Bache M, Bartel F, Kohler T, Lautenschlager C, Blumke K, Wurl P, Schmidt H, Meye A, Hauptmann S. 2005. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene 24(33):5258-5261.
57. Vader G, Kauw JJ, Medema RH, Lens SM. 2005. Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep 7:85-92.
58. Vegran F, Boidot R, Oudin C, Riedinger JM, Lizard-Nacol S. 2005. Distinct expression of Survivin splice variants in breast carcinomas. Int J Oncol 27(4):1151-1157.
59. Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y. 2005. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 310(5753):1499-1504.
60. Wang HW, Sharp TV, Koumi A, Koentges G, Boshoff C. 2002. Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpes-virus which resembles a spliced variant of human survivin. EMBO J 21(11):2602-2615.
61. Wang L, Zhang GM, Feng ZH. 2003. Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line. Acta Pharmacol Sin 24(12):1235-1240.
62. Wheatley SP, Henzing AJ, Dodson H, Khaled W, Earnshaw WC. 2004. Aurora-B phosphorylation in vitro identifies a residue of Survivin that is essential for its localization and binding to INCENP in vivo. J Biol Chem 279(7):5655-5660.
63. Yang D, Welm A, Bishop JM. 2004. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 101(42):15100-15105.
64. Zhang T, Fields JZ, Ehrlich SM, Boman BM. 2004a. The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 308(2):434-437.
65. Zhang Y, Nagata Y, Yu G, Nguyen HG, Jones MR, Toselli P, Jackson CW, Tatsuka M, Todokoro K, Ravid K. 2004b. Aberrant quantity and localization of Aurora-B/AIM-1 and survivin during megakaryocyte polyploidization and the consequences of Aurora-B/AIM-1-deregulated expression. Blood 103(10):3717-3726.
66. Zhang M, Latham DE, Delaney MA, Chakravarti A. 2005a. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24(15):2474-2482.
67. Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, Shipley WU, Chakravarti A. 2005b. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 64(3):293-302.
68. Zheng W, Ma X, Wei D, Wang T, Ma Y, Yang S. 2005. Molecular cloning and bioinformatics analysis of a novel spliced variant of survivin from human breast cancer cells. DNA Seq 16(5):321-328.
69. Zhou J, O'Brate A, Zelnak A, Giannakakou P. 2004. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer Res 64(23):8708-8714.
70. Zhu N, Gu L, Findley HW, Li F, Zhou M. 2004. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 23:7545-7551.